China Resources Pharmaceutical Group Ltd. (3320) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sino Biopharmaceutical Ltd.

WuXi AppTec Co., Ltd.

China Medical System Holdings Ltd.

Sinopharm Group Co., Ltd.

China Resources Pharmaceutical Group Ltd.

Hygeia Healthcare Holdings Co., Ltd.

Hansoh Pharmaceutical Group Co., Ltd.

Innovent Biologics, Inc.

Akeso, Inc.

HUTCHMED (China) Ltd.

BeiGene Ltd.

Why is China Resources Pharmaceutical Group Ltd. ?

High Debt Company with a Debt to Equity ratio (avg) at times

Poor long term growth as Operating profit has grown by an annual rate 9.87% of over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

Poor long term growth as Operating profit has grown by an annual rate 9.87% of over the last 5 years

Flat results in Dec 24

INTEREST(HY) At HKD 1,197.51 MM has Grown at 55.02%
DIVIDEND PAYOUT RATIO(Y) Lowest at 43.48%
DEBT-EQUITY RATIO (HY) Highest at 110.25 %

With ROE of 19.66%, it has a Very Expensive valuation with a 0.60 Price to Book Value

Over the past year, while the stock has generated a return of -14.15%, its profits have risen by 15% ; the PEG ratio of the company is 0.2

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -14.15% returns in the last 1 year, the stock has also underperformed Hang Seng Hong Kong in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is China Resources Pharmaceutical Group Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

China Resources Pharmaceutical Group Ltd.

-15.26%

-0.95

23.34%

Hang Seng Hong Kong

27.36%

1.03

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.98%

EBIT Growth (5y)

9.87%

EBIT to Interest (avg)

3.87

Debt to EBITDA (avg)

2.67

Net Debt to Equity (avg)

1.09

Sales to Capital Employed (avg)

1.87

Tax Ratio

23.92%

Dividend Payout Ratio

25.38%

Pledged Shares

Institutional Holding

ROCE (avg)

12.46%

ROE (avg)

16.20%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.60

EV to EBIT

6.93

EV to EBITDA

5.37

EV to Capital Employed

0.81

EV to Sales

0.31

PEG Ratio

0.20

Dividend Yield

ROCE (Latest)

11.64%

ROE (Latest)

19.66%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for China Resources Pharmaceutical Group Ltd.

Net Sales

Highest at HKD 140,022.98 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (HKD MM)

Net Sales

At HKD 140,022.98 MM has Grown at 32.39%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (HKD MM)

Raw Material Cost

Fallen by -2% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at HKD 1,875.31 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (HKD MM)

Depreciation

At HKD 1,875.31 MM has Grown at 6.3%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for China Resources Pharmaceutical Group Ltd.

Interest

At HKD 1,197.51 MM has Grown at 55.02%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)

EPS

Lowest at HKD 0.13

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (HKD)

Debt-Equity Ratio

Highest at 110.25 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Dividend per share

Lowest at HKD 0

in the last five years

MOJO Watch

Company is distributing lower dividend than previous years

DPS (HKD)

Dividend Payout Ratio

Lowest at 43.48%

in the last five years

MOJO Watch

Company is distributing lower proportion of profits generated as dividend

DPR (%)